Navigation Links
Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
Date:8/17/2011

TARRYTOWN, N.Y., Aug. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that clinical data from four separate clinical studies of EYLEA™ (aflibercept injection) will be presented at the upcoming American Society of Retina Specialists (ASRS) meeting on Sunday, August 21 and Monday, August 22, 2011 in Boston, Massachusetts.

The presentations are:

  • "Analysis of 2,457 Patients in the Phase 3 VIEW 1 and VIEW 2 Studies Comparing VEGF Trap-Eye and Ranibizumab in Neovascular AMD" will be presented by Jeffrey S. Heier, M.D. on Sunday, August 21 at 8:21 a.m.  

  • "One-year Results of the DA VINCI Study of VEGF Trap-Eye in DME" will be presented by Diana V. Do, M.D. on Sunday, August 21 at 2:48 p.m.  

  • "The 6-Month (Primary Endpoint) Results of the Phase 3 GALILEO Study: VEGF Trap-Eye in CRVO" will be presented by Jean-Francois Korobelnik, M.D. on Monday, August 22 at 8:20 a.m.  

  • "Trap-Eye in CRVO: 1-year Results of the Phase 3 COPERNICUS Study" will be presented by W. Lloyd Clark, M.D. on Monday, August 22 at 8:28 a.m.  

  • About EYLEA™ (aflibercept injection)Vascular Endothelial Growth Factor (VEGF) is a naturally occurring protein in the body.  Its normal role in a healthy organism is to trigger formation of new blood vessels (angiogenesis) supporting the growth of the body's tissues and organs.  However, in certain diseases, such as age-related macular degeneration, it is also associated with the growth of abnormal new blood vessels in the eye, which exhibit vascular permeability and lead to edema.  

    EYLEA, also known as VEGF Trap-Eye, is a fully human fusion protein, consisting of portions of VEGF receptors 1 and 2, that binds all forms of VEGF-A along with the related Placental Growth Factor (PlGF).  EYLEA is a specific and highly potent blocker of these growth factors.  EYLEA is specially purified and contains iso-osmotic buffer concentrations, allowing for injection into the eye.

    Regeneron and Bayer HealthCare are collaborating on the global development of EYLEA for the treatment of neovascular age-related macular degeneration (wet AMD), central retinal vein occlusion (CRVO), diabetic macular edema (DME), and other eye diseases and disorders.  Bayer submitted an application for marketing authorization in Europe in wet AMD in June 2011.

    Bayer HealthCare will market EYLEA™ (aflibercept injection) outside the United States, where the companies will share equally the profits from any future sales of EYLEA.  Regeneron maintains exclusive rights to EYLEA in the United States.

    About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration, central retinal vein occlusion, and diabetic macular edema), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.Contact Information:Michael Aberman, M.D.

    Peter DworkinInvestor Relations

    Corporate Communications914.345.7799

    914.345.7640michael.aberman@regeneron.com

    peter.dworkin@regeneron.com
    '/>"/>

    SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
    2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
    3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
    4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
    5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
    6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
    7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
    8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
    9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
    10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
    11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2017)...  Dr. Echenberg, founder of Echenberg Institute, is announcing a new safe ... from painful intercourse and other painful pelvic pain conditions such as pelvic ... ... ... Florida -based start-up company, VuVatech LLC, fills a void in the ...
    (Date:7/10/2017)... 10, 2017 The Institute for In Vitro ... the recipient of a VITROCELL® inhalation exposure system thanks ... Consortium. The device, which is designed to replace animals ... lung cells to airborne test materials in an environment ... VITROCELL® system for testing combustible tobacco products, as well ...
    (Date:7/10/2017)... , July 10, 2017 Locus Biosciences Inc. ... to support the development of CRISPR-Cas3 antimicrobial therapeutics. Financing ... a leading Chinese Internet services provider, and joined by ... multiple infectious disease product programs targeting antibiotic resistant infections ... Founded by Dr. Rodolphe Barrangou and ...
    Breaking Medicine Technology:
    (Date:7/24/2017)... ... July 24, 2017 , ... A CDC study shows that, although people are taking more ... 18 to 29), had at least one case of sunburn within the past year. It’s ... people to ignore the issue. However, only recently have people become conscientious of the risks ...
    (Date:7/24/2017)... ... 2017 , ... Anyone who uses scales know they have limits; a small ... that same scale to dispense medication. The first example is an issue of capacity, ... it is important to have the right balance for the process. METTLER TOLEDO’s new ...
    (Date:7/24/2017)... ... July 24, 2017 , ... Sharon Kleyne, host of the nationally syndicated ... VoiceAmerica sponsored by Nature’s Tears® EyeMist® recently talked on the air about an alarming ... , The article by Zidor Aldama described the situation in which Chinese children are ...
    (Date:7/24/2017)... ... July 24, 2017 , ... Paul Vitenas, MD, FACS is excited to report ... invited to attend Allergan’s recent meeting with their Plastics Advisory Board. As one of ... Allergan is bringing a newly defined structure to the aesthetics market. Dr. Vitenas ...
    (Date:7/24/2017)... ... 24, 2017 , ... The Magic Wand® Rechargeable, the top-of-the-line ... favorite sex toy. Created in collaboration with website Kinkly.com, the award was the ... The Magic Wand Rechargeable won in stiff competition from brands such as Lelo, ...
    Breaking Medicine News(10 mins):